HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Angiopeptin versus placebo for reductin of restenosis after PTCA treatment. A randomized, double-blind study].

Abstract
Angiopeptin, a somatostatin analogue, inhibits intimal hyperplasia after (percutaneous transluminal coronary angioplasty) (PTCA) in several animal models. This pilot study sought to determine the effect of subcutaneous infusion of angiopeptin on clinical events and restenosis in patients undergoing successful PTCA. One hundred and twelve patients were randomized to receive continuous subcutaneous angiopeptin (750 micrograms/day) or placebo infusion from the day before PTCA and for the following four days in a double-blind study. Eighty patients had a successful PTCA, and 75 of these patients with 94 lesions underwent angiography 6 +/- 2 months after PTCA. All 112 patients underwent clinical follow-up at 12 months. The 12-month event rate (death, myocardial infarction, coronary artery bypass grafting and re-PTCA) was reduced from 34% to 25% (p = 0.30) by angiopeptin by intention to treat analysis. Restenosis (> or = 50% diameter stenosis) was significantly reduced in lesions treated with angiopeptin (12% vs 40%; p = 0.003). Late lumen loss was also significantly reduced after angiopeptin treatment (0.12 +/- 0.46 mm vs 0.52 +/- 0.64 mm; p = 0.003). In conclusion, continuous subcutaneous angiopeptin infusion for five days tended to decrease clinical events and restenosis after PTCA.
AuthorsU H Eriksen, O Amtorp, J P Bagger, H Emanuelsson, M Foegh, K I Saunamäki, M Schaeffer, P Thayssen, H Orskov, R E Kuntz, J J Popma
JournalUgeskrift for laeger (Ugeskr Laeger) Vol. 158 Issue 46 Pg. 6605-8 (Nov 11 1996) ISSN: 0041-5782 [Print] Denmark
Vernacular TitleAngiopeptin versus placebo til reduktion af restenose efter PTCA-behandling. En randomiseret, dobbeltblind undersøgelse.
PMID8966826 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Cardiovascular Agents
  • Oligopeptides
  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
Topics
  • Adolescent
  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary (adverse effects)
  • Cardiovascular Agents (administration & dosage)
  • Coronary Disease (prevention & control, therapy)
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Oligopeptides (administration & dosage)
  • Peptides, Cyclic
  • Recurrence
  • Somatostatin (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: